{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:30:00Z","timestamp":1767652200341,"version":"build-2065373602"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reproductive Toxicology"],"published-print":{"date-parts":[[2005,5]]},"DOI":"10.1016\/j.reprotox.2005.01.004","type":"journal-article","created":{"date-parts":[[2005,2,8]],"date-time":"2005-02-08T10:15:25Z","timestamp":1107857725000},"page":"165-173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Embryotoxic effects of CKD-602, a new camptothecin anticancer agent, in rats"],"prefix":"10.1016","volume":"20","author":[{"given":"Moon-Koo","family":"Chung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong-Choon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Seop","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.reprotox.2005.01.004_bib1","first-page":"461","article-title":"Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC 100880)","volume":"54","author":"Gottlieb","year":"1970","journal-title":"Cancer Chemother Rep"},{"key":"10.1016\/j.reprotox.2005.01.004_bib2","first-page":"515","article-title":"Phase I clinical trial of weekly and daily treatment with camptothecin (NSC 100880)","volume":"56","author":"Muggia","year":"1972","journal-title":"Cancer Chemother Rep"},{"key":"10.1016\/j.reprotox.2005.01.004_bib3","first-page":"95","article-title":"Phase II study of camptothecin (NSC 100880) in the treatment of advanced gastrointestinal cancer","volume":"56","author":"Moertel","year":"1972","journal-title":"Cancer Chemother Rep"},{"key":"10.1016\/j.reprotox.2005.01.004_bib4","first-page":"1","article-title":"CPT-11: from DNA topology to clinical activity","volume":"23","author":"Bleiberg","year":"1996","journal-title":"Semin Oncol"},{"key":"10.1016\/j.reprotox.2005.01.004_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000011923","article-title":"Topotecan\u2014a novel topoisomerase I inhibitor: pharmacology and clinical experience","volume":"56","author":"Kolimannsberger","year":"1999","journal-title":"Oncology"},{"key":"10.1016\/j.reprotox.2005.01.004_bib6","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1200\/JCO.1996.14.4.1236","article-title":"Phase I and pharmacokinetic study of 9-aminocamptothecin given as a 72-hour infusion in adult cancer patients","volume":"14","author":"Dahut","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.reprotox.2005.01.004_bib7","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1007\/s002800051077","article-title":"Clinical pharmacology of camptothecins","volume":"42","author":"Iyer","year":"1998","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.reprotox.2005.01.004_bib8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0167-4781(98)00130-4","article-title":"Clinical applications of the camptothecins","volume":"1400","author":"Takimoto","year":"1998","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.reprotox.2005.01.004_bib9","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/jps.2600810718","article-title":"A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues","volume":"81","author":"Fassberg","year":"1992","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.reprotox.2005.01.004_bib10","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1021\/jm00123a038","article-title":"Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity","volume":"32","author":"Hertzberg","year":"1989","journal-title":"J Med Chem"},{"key":"10.1016\/j.reprotox.2005.01.004_bib11","first-page":"369","article-title":"Mutagenic activity of topoisomerase I inhibitors","volume":"1","author":"Hashimoto","year":"1995","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.reprotox.2005.01.004_bib12","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/S0959-8049(98)00229-9","article-title":"Camptothecins: a review of their development and schedules of administration","volume":"34","author":"O\u2019Leary","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.reprotox.2005.01.004_bib13","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/BF02975379","article-title":"Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor","volume":"21","author":"Lee","year":"1998","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.reprotox.2005.01.004_bib14","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0378-5173(02)00099-6","article-title":"Preformulation studies of a novel camptothecin anticancer agent, CKD-602: physicochemical characterization and hydrolytic equilibrium kinetics","volume":"239","author":"Kim","year":"2002","journal-title":"Int J Pharm"},{"key":"10.1016\/j.reprotox.2005.01.004_bib15","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1749-6632.2000.tb07055.x","article-title":"Preclinical and phase I clinical studies with Ckd-602, a novel camptothecin derivative","volume":"922","author":"Lee","year":"2000","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.reprotox.2005.01.004_bib16","first-page":"272","article-title":"Safety pharmacology of CKD-602, a novel anticancer agent","volume":"53","author":"Kim","year":"2003","journal-title":"Arzneimittel Forschung"},{"key":"10.1016\/j.reprotox.2005.01.004_bib17","first-page":"129","article-title":"Genotoxicity studies of an anticancer agent of camptothecin series, CKD-602","volume":"18","author":"Ha","year":"1998","journal-title":"Environ Mutag Carcinog"},{"key":"10.1016\/j.reprotox.2005.01.004_bib18","first-page":"125","article-title":"Reproduction and developmental studies of CPT-11: study on administration of the test substance during the period of organogenesis in rats","volume":"24","author":"Itabashi","year":"1990","journal-title":"Clin Rep"},{"key":"10.1016\/j.reprotox.2005.01.004_bib19","first-page":"157","article-title":"Reproduction and developmental studies of CPT-11: study on administration of the test substance during the period of organogenesis in rabbits","volume":"24","author":"Itabashi","year":"1990","journal-title":"Clin Rep"},{"key":"10.1016\/j.reprotox.2005.01.004_bib20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/10520292609115636","article-title":"A note on the staining of the skeleton of cleared specimens with Alizarin Red S","volume":"1","author":"Dawson","year":"1926","journal-title":"Stain Technol"},{"key":"10.1016\/j.reprotox.2005.01.004_bib21","series-title":"Principles and techniques","first-page":"262","article-title":"Methods for administering agents and detecting malformations in experimental animals in teratology","author":"Wilson","year":"1965"},{"key":"10.1016\/j.reprotox.2005.01.004_bib22","first-page":"23","article-title":"A microdissection method for detecting thoracic visceral malformations in mouse and rat fetuses","volume":"14","author":"Nishimura","year":"1974","journal-title":"Cong Anom"},{"key":"10.1016\/j.reprotox.2005.01.004_bib23","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/(SICI)1096-9926(199704)55:4<249::AID-TERA5>3.0.CO;2-W","article-title":"Terminology of developmental abnormalities in common laboratory animals (Version 1)","volume":"55","author":"Wise","year":"1997","journal-title":"Teratology"},{"key":"10.1016\/j.reprotox.2005.01.004_bib24","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1741-4520.1987.tb00703.x","article-title":"Spontaneous malformations in laboratory animals: frequency of external, internal and skeletal malformations in rats, rabbits and mice","volume":"27","author":"Morita","year":"1987","journal-title":"Cong Anom"},{"key":"10.1016\/j.reprotox.2005.01.004_bib25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/009841001455508","article-title":"Historical control data for developmental toxicity study in Sprague-Dawley rats","volume":"17","author":"Kim","year":"2001","journal-title":"J Toxicol Public Health"},{"key":"10.1016\/j.reprotox.2005.01.004_bib26","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s004320050255","article-title":"Novel anticancer drugs in Japan","volume":"125","author":"Ogawa","year":"1999","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.reprotox.2005.01.004_bib27","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2131\/jts.11.SupplementI_195","article-title":"Reproduction studies of VP 16-213 (II)\u2014oral administration to rats during the period of fetal organogenesis","volume":"11","author":"Takahashi","year":"1986","journal-title":"J Toxicol Sci"},{"key":"10.1016\/j.reprotox.2005.01.004_bib28","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2131\/jts.11.SupplementI_227","article-title":"Reproduction studies of VP 16-213 (III)\u2014oral administration to rabbits during the period of fetal organogenesis","volume":"11","author":"Takahashi","year":"1986","journal-title":"J Toxicol Sci"},{"key":"10.1016\/j.reprotox.2005.01.004_bib29","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/(SICI)1520-6866(1999)19:3<233::AID-TCM6>3.0.CO;2-8","article-title":"Developmental toxicity of the topoisomerase inhibitor, etoposide, in rabbits after intravenous administration","volume":"19","author":"Nagao","year":"1999","journal-title":"Teratogen Carcinigen Mutagen"},{"key":"10.1016\/j.reprotox.2005.01.004_bib30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/tera.1420180107","article-title":"Teratogenic and cytogenetic effects of some plant-derived antitumor agents (vincristine, colchicine, maytansine, VP-16-213 and VM-26) in mice","volume":"18","author":"Sieber","year":"1978","journal-title":"Teratology"},{"key":"10.1016\/j.reprotox.2005.01.004_bib31","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/tera.1420310115","article-title":"Maternal toxicity: a possible etiological factor in embryo-fetal deaths and fetal malformations of rodent-rabbit species","volume":"31","author":"Khera","year":"1985","journal-title":"Teratology"},{"key":"10.1016\/j.reprotox.2005.01.004_bib32","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/tcm.1770070309","article-title":"Maternal toxicity in human and animals: effects on fetal development and criteria for detection","volume":"7","author":"Khera","year":"1987","journal-title":"Teratogen Carcinogen Mutagen"},{"key":"10.1016\/j.reprotox.2005.01.004_bib33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/tcm.1770050103","article-title":"The effect of acute maternal toxicity on fetal development in the mouse","volume":"5","author":"Kavlock","year":"1985","journal-title":"Teratogen Carcinogen Mutagen"},{"key":"10.1016\/j.reprotox.2005.01.004_bib34","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0300-483X(89)90050-4","article-title":"An overview of maternal toxicity and prenatal development: considerations for developmental toxicity hazard assessments","volume":"59","author":"Chernoff","year":"1989","journal-title":"Toxicology"},{"key":"10.1016\/j.reprotox.2005.01.004_bib35","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0890-6238(99)00035-0","article-title":"Correlation between maternal toxicity and embryo\/fetal effects","volume":"13","author":"Chahoud","year":"1999","journal-title":"Reprod Toxicol"}],"container-title":["Reproductive Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890623805000080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890623805000080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:22:44Z","timestamp":1760188964000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890623805000080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["S0890623805000080"],"URL":"https:\/\/doi.org\/10.1016\/j.reprotox.2005.01.004","relation":{},"ISSN":["0890-6238"],"issn-type":[{"type":"print","value":"0890-6238"}],"subject":[],"published":{"date-parts":[[2005,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Embryotoxic effects of CKD-602, a new camptothecin anticancer agent, in rats","name":"articletitle","label":"Article Title"},{"value":"Reproductive Toxicology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reprotox.2005.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}